The global digital biomarkers market is projected to be worth over USD 22 billion by 2030, growing at a CAGR of 35.74%,
Advances in information technology and biomedical science have enabled the development of digital solutions for biomarkers, which, owing to the myriad of pertinent applications, are being increasingly adopted in modern healthcare practices Roots Analysis has announced the addition of u201cDigital Solutions for Biomarkers Market, 2021-2030u201d report to its list of offerings. Digital solutions for biomarkers are modern solutions that are capable of generating, collecting, and tracking medical data. From this data, digital biomarkers that offer insights into anatomical, physiological, and molecular events, and even behavior-related patterns in humans, have been acknowledged as viable inputs to understand, track, monitor and / or predict health-related outcomes. In the current pandemic, medical professionals are trying to identify digital biomarkers that can facilitate the successful screening / diagnosis of COVID-19 patients, remotely. To order this 270 page report, which features 135 figures and 140 tables, please visit https://www.rootsanalysis.com/reports/digital-biomarkers-market.html Key Market Insights Over 45 digital solutions for biomarkers are currently available / under development Over 70% of the aforementioned solutions are offered either as combinations of software applications and devices or as standalone software solutions, targeting more than 30 unique target indications. Over 85% of digital solutions for biomarkers are intended for patient monitoring purposes Such solutions are currently available / being developed to monitor various digital biomarkers associated with neurological disorders (22%), respiratory disorders (17%), and infectious disorders (15%). In fact, over 15% of these solutions are being extensively used for monitoring patients with COVID-19. 40 global events, focused on digital solutions for biomarkers, have been organized since 2016 Around 40% of these were conferences, involving more than 25 unique organizers. Close to 50% of such events have been / are being organized in the US. Nearly USD 950 million invested by both private and public investors in this domain ~70% of the total capital raised by digital solutions for biomarkers developers was from venture capital funding, featuring the contributions of over 150 investors. In addition, over 65% was invested in companies focused on development of physiological / vocal digital biomarkers. Partnership activity in this field has grown at a CAGR of over 60%, between 2016 and 2020 More than 65% of the reported deals were established in the last two years (since 2019), with the maximum activity being reported in 2020. Majority of the instances captured in the report were research and development agreements (24%) and product / technology integration agreements (15%). Further, more than 40% of these agreements have been signed for digital solutions for physiological biomarkers. North America and Europe are anticipated to capture over 65% of the market share by 2030 The market in Asia-Pacific regions is anticipated to grow at a relatively faster pace (41.03%). In 2030, digital solutions capturing vocal biomarkers are likely to represent the largest market share, in terms of revenues from product sales (37%), followed by those intended to capture physiological biomarkers (32%) and idiosyncratic biomarkers (16%). To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/digital-biomarkers-market/request-sample.html Key Questions Answered uf0a7tWho are the leading players engaged in the development of digital solutions for biomarkers? uf0a7tWhich are the popular therapeutic areas where digital biomarkers are currently relevant? uf0a7tWhat kind of global level events related to digital biomarkers, have been organized in the recent past? uf0a7tWhat is the trend of capital investments in the digital biomarkers market? uf0a7tWhich partnership models are most commonly adopted by stakeholders in this industry? uf0a7tWhat is the tole of big pharma players engaged in this domain? uf0a7tHow has the COVID-19 pandemic impacted the digital biomarkers market? uf0a7tWhat are the opportunities available for digital solutions for biomarkers in emerging markets? uf0a7tHow is the current and future opportunity likely to be distributed across key market segments? uf0a7tWhat are the anticipated future trends related to digital solutions for biomarkers market? The USD 22.6 billion (by 2030) financial opportunity within the digital solutions for biomarkers market has been analyzed across the following segments: uf0a7tContent of Solution uf0a7tSoftware Application AI Support uf0a7tSoftware Application Device uf0a7tStandalone Software Application uf0a7tOther Contents of Solutions uf0a7tPurpose of Solution uf0a7tDiagnosis uf0a7tEarly Screening uf0a7tMonitoring uf0a7tPredictive Insights uf0a7tType of Biomarker uf0a7tCognitive Biomarkers uf0a7tIdiosyncratic Biomarkers uf0a7tPhysiological Biomarkers uf0a7tVocal Biomarkers uf0a7tOther Biomarkers uf0a7tTherapeutic Areas uf0a7tAutoimmune Disorders uf0a7tCardiovascular Disorders uf0a7tInfectious Disorders uf0a7tMental Health Problems uf0a7tNeurological Disorders uf0a7tRespiratory Disorders uf0a7tSubstance Use Disorders uf0a7tOthers uf0a7tBusiness Model uf0a7tBusiness to Business (Healthcare Providers, Payers, Employers and Pharmaceutical Companies) uf0a7tBusiness to Consumer (Patients and Caregivers) uf0a7tKey Geographical Regions uf0a7tNorth America uf0a7tEurope uf0a7tAsia-Pacific uf0a7tMiddle East and North Africa (MENA) uf0a7tRest of the world The report features inputs from eminent industry stakeholders, according to whom, digital biomarkers are soon likely to witness increased adoption given their broad scope of applications and the availability of technologies that enable such biological inputs to be remotely identified and processed. The report includes detailed transcripts of the discussions held with following industry experts: uf0a7tEdouard Gasser (Co-Founder and Chief Executive Officer, Tilak Healthcare) uf0a7tMichael Seggev (Chief Commercial Officer, Vocalis Health) The research covers brief profiles of key players engaged in the development of digital solutions for biomarkers; other popular industry players featured in the report include: uf0a7tAkili Interactive uf0a7tAiCure uf0a7tCogito Corp uf0a7tJanssen Pharmaceuticals uf0a7tHuma uf0a7tMindstrong Health uf0a7tOura uf0a7tPear Therapeutics uf0a7tRoche uf0a7tSonde Health uf0a7tVocalis Health uf0a7tWinterlight Labs For additional details, please visit https://www.rootsanalysis.com/reports/digital-biomarkers-market.html You may also be interested in the following titles: 1.tAI-based Drug Discovery Market: Focus on Deep Learning and Machine Learning, 2020-2030 2.tConnected / Smart Drug Delivery Systems Market by Product Type (Connected Inhalers, Connected Autoinjectors, Connected Pen injectors, Connected Wearable Injectors, Add-On Sensors and Others), Therapeutic Area (Metabolic Disorders, Neurological Disorders, Respiratory Disorders and Others) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2020-2030 3.tDiabetes Monitoring Devices Market by Type of Device (Self-Monitoring Blood Glucose Devices and Continuous Blood Glucose Monitoring Devices), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Type of Self-Monitoring Blood Glucose Device Component (Lancing Devices, Blood Glucose Meters and Testing Strips), Type of Continuous Blood Glucose Monitoring Device Component (Sensors, Transmitters and Receivers), and Key Geographies: Industry Trends and Global Forecasts, 2020-2030 Contact: Gaurav Chaudhary 1 (415) 800 3415 44 (122) 391 1091 Gaurav.Chaudhary@rootsanalysis.com
22 views • 1 slides